Comparative Study of Different Neoadjuvant Therapies Before Radical Hysterectomy in Stage Ib2-IIa2 Cervical Cancer
Comparative Study of Different Neoadjuvant Therapies Before Radical Hysterectomy in Stage Ib2-IIa2 Cervical Cancer
For stage Ib2-IIa2 cervical cancer patients, neoadjuvant therapy followed by radical
 hysterectomy and pelvic lymphadenectomy is one of the managements. Post-operative concurrent
 chemo-radiotherapy is necessary if the patients have high-risk factors, including positive
 surgical margin, parametrium and pelvic nodes. Our previous retrospective study showed that
 combination of neoadjuvant chemotherapy and brachytherapy reduced the proportion of
 post-operative concurrent chemo-radiotherapy compared to neoadjuvant chemotherapy alone.
In the present study, the patients with stage Ib2-IIa2 cervical cancer will receive either
 neoadjuvant chemo/brachytherapy or neoadjuvant chemotherapy before radical hysterectomy and
 pelvic+/- para-aortic lymph node dissection. According to the surgical findings,
 post-operative chemo-radiotherapy will be performed.
Inclusion Criteria:

 -  Histology confirmed cervical cancer

 -  Clinical stage Ib2 or IIa2 (FIGO 2009)

 Exclusion Criteria:

 -  Patients who not suitable for surgery

 -  Personal history of pelvic radiotherapy